1. Disordered mesoporous silica particles: an emerging platform to deliver proteins to the lungs
- Author
-
Aura Rocío Hernández, Ekaterina Bogdanova, Jesus E. Campos Pacheco, Vitaly Kocherbitov, Mikael Ekström, Georgia Pilkington, and Sabrina Valetti
- Subjects
Dried powder inhalation ,protein formulation ,micronised drug carrier ,mesoporous silica particles ,pulmonary drug delivery ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Pulmonary delivery and formulation of biologics are among the more complex and growing scientific topics in drug delivery. We herein developed a dry powder formulation using disordered mesoporous silica particles (MSP) as the sole excipient and lysozyme, the most abundant antimicrobial proteins in the airways, as model protein. The MSP had the optimal size for lung deposition (2.43 ± 0.13 µm). A maximum lysozyme loading capacity (0.35 mg/mg) was achieved in 150 mM PBS, which was seven times greater than that in water. After washing and freeze-drying, we obtained a dry powder consisting of spherical, non-aggregated particles, free from residual buffer, or unabsorbed lysozyme. The presence of lysozyme was confirmed by TGA and FT-IR, while N2 adsorption/desorption and SAXS analysis indicate that the protein is confined within the internal mesoporous structure. The dry powder exhibited excellent aerodynamic performance (fine particle fraction
- Published
- 2024
- Full Text
- View/download PDF